# Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies

> **NCT00040417** · PHASE2 · TERMINATED · sponsor: **Baylor College of Medicine** · enrollment: 15 (—)

## Conditions studied

- Sickle Cell Anemia
- Hemoglobinopathy
- Thalassemia

## Interventions

- **DRUG:** FLUDARABINE
- **DRUG:** CAMPATH-IH
- **PROCEDURE:** Total Body Irradiation
- **DRUG:** FK506
- **DRUG:** G-SCF (Granulocyte-colony stimulating factor)

## Key facts

- **NCT ID:** NCT00040417
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-08
- **Primary completion:** 2003-11-21
- **Final completion:** 2003-11-21
- **Target enrollment:** 15 (—)
- **Why stopped:** unable to accrue patients
- **Last updated:** 2020-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00040417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00040417, "Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00040417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*